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Abstract
Background: Chronic conditions such as coronary heart disease (CHD) challenge health care to provide systematic
and long-lasting disease management. In this study of patients who were revascularized, we examine whether
treatment pathways leading to coronary revascularisation differ between patients with and without diabetes.
Methods: This retrospective, nationwide register-based study in Finland in 1998-2007 describes temporal trends in
the proportions of 1) revascularisations performed at the first treatment period, and 2) suboptimal treatment
pathways to revascularisations, i.e. pathways containing several cardiac emergency hospitalisations. Differences
between patient groups were examined using a logistic regression model adjusting for age, comorbidity, and
region.
Results: Among patients who underwent revascularisation, upward trends were found in the proportions of
revascularisations performed during first hospital admission: among men with CHD alone, the percentages were
28% in 1998 and 77% in 2007; among men with insulin-dependent diabetes (IDD) they were 16% vs. 58% for the
respective years; and among men with non-insulin dependent diabetes (NIDD) they were 25% vs. 69%,
respectively. Among women the percentages were for non-diabetic group 32% vs. 77%; for IDD group 36% vs.
64%; and for NIDD group 33% vs. 73% for the respective years. Patients with diabetes were less likely to undergo
revascularisation during the first hospital admission, in 2005-2007, the odds ratio (OR) for IDD among men was 0.52
(95% confidence interval 0.42-0.64) and for NIDD among men it was 0.79 (95% CI 0.73-0.86) compared to patients
with CHD alone. The respective ORs among women were 0.59 (95% CI 0.44-0.78), and 0.83 (95% CI 0.74-0.93).
Conclusions: Treatment practices changed substantially during the study period to favour performing
revascularisation during the first hospital admission. The large increase in coronary angioplasty operations is likely
to be an important factor behind these changes. However, fewer operations are performed during the first CHD
hospitalisation of diabetic patients who undergo coronary revascularisation and they experience more often
emergency hospital admissions before the operation than patients without diabetes. To avoid adverse cardiac
events, more attention is needed in managing diabetic CHD patients’ referral pathways to revascularisation.
Background
Research evidence suggests that coronary heart disease
(CHD) treatment among patients with diabetes is not
completely in line with clinical guidelines. Furthermore,
treatment has been reported as not being as intensive as
among patients without diabetes [1-3]. In Finland medi-
cation to prevent adverse CHD events has been reported
to be suboptimal for hospitalized diabetic persons with
myocardial infarction (MI) and for ambulatory CHD
patients [4-6]. Similarly, access to revascularisation
among patients with diabetes has been found to be
poorer than among patients without diabetes [7].
In Finland a notable increase of resources to perform
revascularisations took place in the 1990s and a national
diabetes prevention and treatment programme was
launched in 2000. The programme prominently under-
lines diabetes as a vascular disease; patients without any
previous coronary events but diagnosed with diabetes
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onary event equivalent to that among patients with a
previous MI [7-9].
However, little is known of the development of treat-
ment practices in coronary care and whether changes in
these practices have had an effect on pathways of treat-
ment leading to coronary revascularisation for different
patient groups. More information is also needed on
whether the increase in resources for invasive cardiac
treatment and the implementation of the national dia-
betes programme have been followed by changes in
treatment practices and possible differences in them
among CHD patients with and without diabetes.
In this register-based cohort study that included all
patients who underwent a coronary revascularisation
operation between 1998 and 2007 in Finland, we
examined the time trends of coronary revascularisation
operations and compared patients with diabetes to
non-diabetic CHD patients. Furthermore, we explored
whether the increase in revascularisation rates was
associated with treatment pathways leading to
revascularisation.
Methods
Patient population
The study is based on individual-level nationwide regis-
ter data on CHD patients with or without diabetes who
underwent a coronary revascularisation operation
between January 1, 1998 and December 31, 2007 in Fin-
land. This study was approved by the ethics committee
of the National Institute for Health and Welfare. The
data linkages were done by appropriate statistical autho-
rities as required by Finnish data protection legislation.
The research group received anonymised data in which
individuals were not identifiable.
The total population of patients admitted for first cor-
onary artery bypass graft (CABG) or first percutaneous
coronary intervention (PCI) were identified in the Fin-
nish Hospital Discharge Register [10]. The Hospital Dis-
charge Register includes all surgical operations delivered
in public and private hospitals in Finland. The status of
diabetes and other chronic diseases were additionally
determined from two national health insurance registers:
1) a register on entitlement to elevated reimbursements
for medicine expenditure due to chronic conditions and
2) a register on reimbursed prescriptions. Diabetes type
was determined on the basis of prescription data: per-
sons with continuous insulin usage and no purchases of
medication intended to increase pancreatic insulin
secretion were considered to have insulin dependent
diabetes (IDD) and others to have non-insulin depen-
dent diabetes (NIDD). The algorithm used in the identi-
fication of chronic comorbidities is described in detail
elsewhere [11].
Defining treatment pathways for analysis
To examine differences in treatment pathways leading to
revascularisation, all hospital admissions having CHD as
the main diagnosis during the two years preceding the
revascularisation operation were included in the study
data, and admissions were classified into three categories
(1) elective CHD hospital admission, (2) myocardial
infarction admission, or (3) other emergency CHD
admission. Since emergency admissions signal poor con-
trol of CHD, treatment pathways were categorized on
the basis of the number of emergency admissions due to
CHD or MI before the revascularisation. Treatment
pathways were defined as suboptimal if two or more
emergency hospitalisations occurred during the two
years preceding revascularisation. Furthermore, we
examined revascularisation during the first treatment
period, i.e. during the first continuous chain of hospitali-
sations without discharge home. The analysis of treat-
ment pathways is based on an approach we have
developed for studying access to hospital care using reg-
ister-based data [12].
Statistical analysis
First, we examined trends in the proportions of revascu-
larisations performed during the first treatment period
among three patient groups (IDD, NIDD and no dia-
betes). Second, we examined trends in suboptimal path-
ways in these patient groups. Third, we modelled the
probability of revascularisation in the first treatment
period and suboptimal treatment pathways. In order to
control for confounding due to cluster effects – which
are potentially caused by the multilevel structure of the
data where patients are nested within regions (munici-
palities) – we used conditional logistic regression mod-
elling with region as a stratum [13]. The basic models
were also adjusted for age and type of revascularisation.
We also estimated models with further adjustment for
comorbidities. Odds ratios and their 95% confidence
intervals were calculated for different patient groups and
time periods. All analyses were performed for men and
women separately.
Results
Distributions of the study variables for the CHD popula-
tion with the first coronary revascularisation are pre-
sented in Table 1. In total we analyzed 78 774 pathways
leading to first revascularisations for the period 1998-
2007 in Finland, with the majority performed in the age
group 55-69. The number of first CABGs was 27 654
among men and 9514 among women. The first PCI was
performed for 28 485 men and for 13 121 women.
Hypertension was the most common comorbidity. The
average number of hospitalisations due to CHD during
the two years preceding revascularisation was 1.64
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CHD hospitalisations was higher among diabetic than
non-diabetic patients. During the study period, the
average number of CHD hospitalisations in the two
years period prior to revascularisation decreased in
both genders and all patient groups. The means
decreased from 2.04 (CI 95% 2.02-2.06) in 1998-2000
to 1.31 (CI 95% 1.30-1.32) in 2005-2007 among men
with CHD without diabetes; from 2.51 (CI 95% 2.31-
2.71) in 1998-2000 to 1.41 (CI 95% 1.39-1.43) in 2005-
2007 among male patients with IDD; and from 2.23
(CI 95% 2.22-2.25) in 1998-2000 to 1.41 (CI 95% 1.39-
1.42) in 2005-2007 among male patients with NIDD.
Among women, the means decreased from 1.96 (CI
95% 1.93-1.99) in 1998-2000 to 1.31 (CI 95% 1.30-
1.33) in 2005-2007 among those with CHD without
diabetes; from 2.11 (CI 95% 1.93-2.29) in 1998-2000 to
1.50 (CI 95% 1.40-1.59) in 2005-2007 among female
patients with IDD; and from 2.19 (CI 95% 2.12-2.27) in
1998-2000 to 1.42 (CI 95% 1.38-1.45) in 2005-2007
among female patients with NIDD.
The distributions of CHD hospital admissions in
terms of urgency were similar among patients with
and without diabetes: Among men with diabetes, 50%
of the hospital admissions that were due to CHD were
elective, 27% were myocardial infarction admissions,
and 23% were other emergency admissions for CHD.
Among men without diabetes the proportions were
51%, 25% and 24%, respectively. Among women with
diabetes 42% were elective CHD hospital admissions,
28% myocardial infarction admissions, and 30% were
other emergency CHD admissions, while for women
without diabetes the proportions were 46%, 26% and
28%, respectively.
The proportion of coronary revascularisations per-
formed during the first treatment period increased sys-
tematically from 1998 to 2007 among both men and
women, while the proportions were on a rather similar
level among both genders (Figure 1). The proportions of
revascularisation operations in the first treatment period
were smaller among patients with diabetes compared to
those without (p < 0.001) revascularisation
Table 1 Background characteristics of CHD population in Finland 1998–2007
Men Women
No diabetes
(n)
% IDD
(n)
% NIDD
(n)
% No diabetes
(n)
% IDD
(n)
% NIDD
(n)
%
Revascularisations
year(s):
1998-2007 44 498 1 121 10 520 16 731 651 5 253
1998 3 818 92 678 1 247 46 377
2007 4 422 152 1 202 1 807 74 625
Revascularisations
type:
PCI 23 290 52 506 45 4 689 45 9 925 59 343 53 2 853 54
CABG 21 208 48 615 55 5 831 55 6 806 41 308 47 2 400 46
Age: -39 728 2 54 5 59 1 170 1 42 6 26 0
40-54 9 461 21 375 33 1 396 13 1 516 9 204 31 277 5
55-69 21 093 47 501 45 5 444 52 6 229 37 249 38 1 848 35
70+ 13 216 30 191 17 3 621 34 8 816 53 156 24 3 102 59
Comorbidities:
Hypertension 23 495 53 881 79 8 102 77 11 287 67 536 82 4 484 85
Atrial fibrillation 3 261 7 45 4 1 046 10 1 217 7 29 4 536 10
Cardiac failure 2 730 6 145 13 1 266 12 1 421 8 94 14 964 18
Alcoholism/drug
abuse
963 2 39 3 214 2 87 1 11 2 26 0
Cancer 2 554 6 54 5 663 6 1 100 7 27 4 382 7
COPD and asthma 5 104 11 135 12 1 436 14 2 611 16 97 15 958 18
Depression 611 1 23 2 176 2 263 2 15 2 119 2
Parkinson’s disease 274 1 9 1 98 1 147 1 8 1 66 1
Mental disorder 1 031 2 35 3 364 3 492 3 29 4 255 5
Dementia 105 0 3 0 37 0 67 0 2 0 22 0
Renal insufficiency 119 0 76 7 50 0 29 0 33 5 22 0
Number of CHD hospitalizations,
mean (standard deviation)
1.62 (0.86) 1.87 (1.15) 1.72 (0.99) 1.59 (0.87) 1.71 (0.92) 1.70 (1.04)
Abbreviations: No diabetes, patients without diabetes; IDD, insulin dependent diabetes; NIDD, non-insulin dependent diabetes; PCI, percutaneous coronary
intervention; CABG, coronary artery bypass graft; Number of CHD hospitalizations covers two years period preceding revascularization.
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increased, the number of suboptimal treatment spells
decreased by at least two-thirds in all patient groups. A
clear downward trend of the proportions of suboptimal
treatment pathways were found both among men and
women (Figure 2), but among patients with diabetes,
suboptimal treatment spells were more probable (p <
0.001).
Among men the odds for revascularisation in the first
hospital treatment period were lower among patients
with diabetes compared to those without diabetes in the
period 1998-2000 (Table 2), with the results remaining
the same even after further adjustment for comorbidity.
Similar differences in the odds for revascularisation in
the first hospital admission were found between women
with and without diabetes in 1998-2000, but the differ-
ences did not reach statistical significance. During the
study period the proportion of revascularisations in the
first hospital admission increased rapidly in both gen-
ders and in all patient groups. In 2005-2007 among men
and women the odds for revascularisation in the first
hospital treatment period were lower among patients
with diabetes than patients without diabetes. The adjust-
ment for comorbidities did diminish the differences, but
it did not remove them entirely.
In 1998-2000, men with diabetes were at a higher risk
for suboptimal pathways to revascularisation than those
without diabetes (Table 3). The difference was especially
large among patients with IDD. Even though the adjust-
ment for comorbidity decreased these differences in
both groups of patients with diabetes it did not abolish
them entirely. In 2005-2007, men with diabetes still had
a higher risk for suboptimal pathways to revascularisa-
tion than CHD patients without diabetes. Although con-
trolling for comorbidities diminished the differences,
they remained statistically significant among patients
with IDD. In 1998-2000, women with diabetes were
more at risk for suboptimal pathways to revascularisa-
tion, even after adjusting for comorbidity. The differ-
ences remained even in the period 2005-2007.
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Figure 1 Trends in coronary revascularisation performed at the first treatment period in 1998-2007.
No diabetes
IDDM
NIDDM
0
10
20
30
40
50
60
70
80
0
10
20
30
40
50
60
70
80
98 00 02 04 06 99 01 03 05 07
Men Women
98 00 02 04 06 99 01 03 05 07
% %
100 100
90 90
Figure 2 Trends in suboptimal pathways leading to coronary revascularisation in 1998-2007.
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This study was based on nationwide register data that
included all CHD patients who underwent coronary
revascularisation. It examined hospital treatment path-
ways leading to the operation in Finland between 1998
and 2007. More specifically, we examined the treatment
pathways among CHD patients with diabetes during a
period that saw a large increase in revascularisation
operations. Overall, treatment practices changed sub-
stantially during the study period to favour performing
revascularisation operationsd u r i n gt h ef i r s th o s p i t a l
admission, whether it was an emergency admission or
not. This was true for both men and women and for
patients with and without diabetes. The large increase in
PCIs is likely to be an important factor behind these
changes, as it is likely that CABG will be more often
planned for a subsequent hospitalisation than PCI.
However, patients with diabetes admitted to coronary
revascularisation received relatively fewer operations in
the first CHD hospital admission compared to their
counterparts without diabetes. The differences remained
rather stable during the whole study period. While sub-
optimal treatment pathways decreased substantially dur-
ing the study period, pathways including two or more
emergency admissions were still more common among
patients with diabetes at the end of the study period.
One explanation might be that health services provide a
lower threshold for CHD admission among patients
with diabetes. The average number of hospitalisations
due to CHD was higher among patients with diabetes.
However, distributions of categories for CHD hospitali-
sations were similar in both patient groups. Of all CHD
admissions of men and women with and without dia-
betes, a quarter were due to MI, which was obviously
diagnosed by the same criteria for all patients, that is
using a blood test (troponin-T) with high sensitivity and
specificity. In Finnish hospitals this test was introduced
in 1997-2000 [14]. Other emergency CHD admissions
comprised a quarter of men’sa n dat h i r do fw o m e n ’s
admissions among both diabetic and non-diabetic
patients. Therefore we consider that it is unlikely that
health services provide a substantially different threshold
for CHD admissions for diabetic patients compared to
non-diabetic patients. Neither do these differences in
suboptimal treatment pathways seem to be solely due to
a different case-mix among patients with and without
diabetes, since taking into account differential comor-
bidity between the patient groups did not eliminate the
Table 2 Odds-ratios for revascularisation at first CHD hospitalisation by gender and history of diabetes
Men Women
Age adjusted Comorbidity adjusted Age adjusted Comorbidity adjusted
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
1998-2000 No diabetes 1.00 ref. 1.00 ref. 1.00 ref. 1.00 ref.
IDD 0.66 (0.49-0.89) 0.73 (0.54-0.99) 0.68 (0.47-1.00) 0.76 (0.52-1.11)
NIDD 0.80 (0.71-0.89) 0.86 (0.77-0.96) 0.88 (0.77-1.02) 0.95 (0.83-1.10)
2005-2007 No diabetes 1.00 ref. 1.00 ref. 1.00 ref. 1.00 ref.
IDD 0.59 (0.48-0.73) 0.52 (0.42-0.64) 0.53 (0.40-0.70) 0.59 (0.44-0.78)
NIDD 0.86 (0.80-0.94) 0.79 (0.73-0.86) 0.77 (0.69-0.87) 0.83 (0.74-0.93)
All models are adjusted for age, type of revascularization (PCI or CABG), and region. Additional comorbidity adjustment is done for hypertension, atrial fibrillation,
cardiac failure, alcoholism or drug abuse, cancer, COPD and asthma, depression, Parkinson’s disease, psychotic mental disorders, dementia, and renal
insufficiency. Abbreviations: No diabetes, patients without diabetes; IDD, insulin dependent diabetes; NIDD, non-insulin dependent diabetes; OR, odds ratio; CI,
confidence interval.
Table 3 Odds-ratios for suboptimal pathway leading to revascularisation by gender and history of diabetes
Men Women
Age adjusted Comorbidity adjusted Age adjusted Comorbidity adjusted
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
1998-2000 No diabetes 1.00 ref. 1.00 ref. 1.00 ref. 1.00 ref.
IDD 2.02 (1.52-2.67) 1.67 (1.26-2.22) 1.79 (1.18-2.70) 1.52 (1.00-2.30)
NIDD 1.29 (1.15-1.44) 1.12 (1.00-1.26) 1.44 (1.24-1.67) 1.28 (1.10-1.49)
2005-2007 No diabetes 1.00 ref. 1.00 ref. 1.00 ref. 1.00 ref.
IDD 2.46 (1.74-3.46) 1.95 (1.38-2.76) 2.29 (1.46-3.57) 1.91 (1.22-3.00)
NIDD 1.28 (1.10-1.49) 1.12 (0.96-1.30) 1.47 (1.22-1.77) 1.30 (1.08-1.57)
All models are adjusted for age and type of revascularization (PCI or CABG), and region. Additional comorbidity adjustment is done for hypertension, atrial
fibrillation, cardiac failure, alcoholism or drug abuse, cancer, COPD and asthma, depression, Parkinson’s disease, psychotic mental disorders, dementia, and renal
insufficiency. Abbreviations: No diabetes, patients without diabetes; IDD, insulin dependent diabetes; NIDD, non-insulin dependent diabetes; OR, odds ratio; CI,
confidence interval.
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sation in our models, and that did not explain the differ-
ences. Adjustment for region using conditional logistic
regression assured that confounding due to cluster
effects was adequately controlled.
We made further sensitivity analyses by adjusting for
the MI during the two years period preceding the opera-
tion. These analyses revealed that persons with MI had
clearly higher odds to undergo revascularisation at their
first hospitalisation, and slightly higher odds for the sub-
optimal pathways leading to CABG. The differences
between patients with and without diabetes, however,
remained the same or slightly increased after adjustment
for MI. The interpretations of the results did not
change, but these sensitivity analyses suggest that our
findings were rather conservative.
Adjusting for changes in the characteristics of the
patient population over time, we modelled specific time
periods at the beginning and end of study, comparing at
both time points the non-diabetic patients to those with
IDD or NIDD. Possible changes in the patient popula-
tion included an increase in the number of patients with
diabetes [15], a shift in CHD incidence towards elderly
persons, an increased number of revascularisations, and
a more precise technology used in determining the need
for revascularisation.
The ten-year study period allowed us to examine
changes in treatment practices among both diabetic and
non-diabetic patient groups. Since the data cover all
public and private hospitals, we were able to examine
the total population of patients undergoing a coronary
revascularisation operation during the study period.
The quality and coverage of the Finnish Hospital Dis-
charge Register has been reported to be generally good
and particularly good among patients with MI [16,17].
Information on chronic diseases was also obtained from
two other registers: a register on the reimbursement of
prescriptive medicine costs and a register on persons eli-
gible for elevated mandatory health insurance reimbur-
sement of drug costs. Since the prescription register is
an administrative register based on actual reimburse-
ments of medicine costs, its coverage is likely to be very
high. Eligibility for an elevated level of reimbursement
requires a doctor’s certificate confirming that the criteria
set by the Social Insurance Institution are met, with the
certificate reviewed by a medical specialist at the Social
Insurance Institution. The u s eo fa l lt h r e er e g i s t e r s
allowed for a reliable identification of chronic diseases.
When interpreting the results, it is important to bear
in mind that the study population is a retrospective
cohort of hospitalized CHD patients who underwent a
coronary revascularisation operation. Our study cannot
therefore estimate whether access to revascularisation is
inequitable among persons with diabetes compared with
other coronary patients. An earlier study from Finland
does suggest that diabetes decreases the likelihood of
coronary revascularisation [18]. Additionally, the dia-
betes population has clearly higher mortality compared
to others [19,20]. Based on our data, we cannot estimate
the proportion of those in need of revascularisation,
who died before the operation, or who were not revas-
cularised in spite of a need. The issue of equitable
access to revascularisation among patients with and
without diabetes is complex, and there is an ongoing
discussion on whether an initial strategy of revasculari-
sation, or a conservative approach with drugs is most
effective for coronary patients with diabetes [21].
Earlier studies have mainly examined differences in
access to revascularisation instead of pathways to it and
to our knowledge similar studies are scarce. A cohort
study of MI patients admitted to Californian hospitals
found both ethnic and payer group differences in treat-
ment pathways; uninsured and minority patients were
less likely to have treatment pathways leading to revas-
c u l a r i s a t i o n .T h e yw e r el e s sl i k e l yt or e c e i v et h eo p e r a -
tion at the first admission, to be transferred to a
hospital offering revascularisation or to be readmitted to
undergo revascularisation [22]. Other retrospective stu-
dies of selection to health care in CHD (revascularisa-
tion and cardiac rehabilitation) suggest there are
barriers in treatment pathways among older patients,
women and lower socioeconomic groups [23-25].
Our retrospective study design enabled us to examine
treatment pathways leading to revascularisation in dif-
ferent patient groups in terms of hospital care. Earlier
research has reported socioeconomic differences in
access to revascularisation among coronary patients in
g e n e r a la sw e l la sp a t i e n t sw i t hd i a b e t e s[ 7 , 1 8 , 2 6 , 2 7 ] .
Further research is needed on the potential socioeco-
nomic differences in pathways to operations among
patients with diabetes.
Differences between patient groups in the revasculari-
sations performed in the first treatment period may
partly echo delays in clinical decision-making on referral
for revascularisation. Due to complicating conditions
requiring medical attention, diabetic CHD patients and
especially patients with IDD may experience these delays
more often than CHD patients without diabetes. The
registers used in this study lack information on these
clinical details. However, allowing for delays in decision-
making, suboptimal treatment pathways should not be
more common among patients with diabetes. Moreover,
the differences in operations at the first CHD admission
as well as in suboptimal pathways remained even after
adjusting for observable comorbidities. In conclusion,
our results suggest that the differences in the risk of
suboptimal treatment pathways may partly be explained
by treatment practices that are not in accordance with
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that the benefits of revascularisation are similar in both
patients groups.
Conclusions
In general, the number of coronary revascularisations
rose in parallel with increased resources and with chan-
ged treatment practices, putting more emphasis on per-
forming revascularisations on CHD patients during the
first hospital admission. However, among men with IDD
and women with IDD and NIDD, the excess risk for
suboptimal pathways to coronary revascularisation
remained. These results are in line with previous studies
reporting suboptimal use of lipid-lowering medication to
prevent CHD among patients with diabetes [6]; further-
more, while CHD mortality has declined constantly, the
excess mortality among patients with diabetes compared
to the general population has not decreased in recent
years [28]. More attention should be focused on cardiac
care among patients with diabetes in terms of secondary
prevention of adverse cardiac events.
Abbreviations
CABG: coronary artery bypass graft; CHD: coronary heart disease; CI:
confidence interval, IDD insulin dependent diabetes; MI: myocardial
infarction; NIDD: non-insulin dependent diabetes; OR: odds ratio; PCI:
percutaneous coronary intervention
Acknowledgements
This study was financially supported by the Academy of Finland (grant
105244), the Social Insurance Institution in Finland, and the Yrjö Jahnsson
Foundation (grant 5978).
Author details
1Health and Social Services, Service Systems Research Unit, National Institute
for Health and Welfare (THL), Helsinki, Finland.
2Centre for Health and Social
Economics CHESS, National Institute for Health and Welfare (THL), Helsinki,
Finland.
Authors’ contributions
TV wrote the manuscript and analyzed data, RS made the statistic analyses
and wrote and reviewed the manuscript, KM reviewed the manuscript and
contributed to the discussion, UH researched data and reviewed the
manuscript, IK reviewed the manuscript and contributed to the discussion.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 February 2011 Accepted: 3 August 2011
Published: 3 August 2011
References
1. Alter DA, Khaykin Y, Austin PC, Tu JV, Hux JE: Processes and outcomes of
care for diabetic acute myocardial infarction patients in Ontario: do
physicians undertreat? Diabetes Care 2003, 26(5):1427-1434.
2. Norhammar A, Malmberg K, Ryden L, Tornvall P, Stenestrand U, Wallentin L,
Register of Information and Knowledge about Swedish Heart Intensive Care
Admission (RIKS-HIA): Under utilisation of evidence-based treatment
partially explains for the unfavourable prognosis in diabetic patients
with acute myocardial infarction. Eur Heart J 2003, 24(9):838-844.
3. Gitt AK, Schiele R, Wienbergen H, Zeymer U, Schneider S, Gottwik MG,
Senges J, for the MITRA Study Group: Intensive treatment of coronary
artery disease in diabetic patients in clinical practice: results of the
MITRA study. Acta Diabetol 2003, 40:S343-S347.
4. Salomaa V, Pääkkönen R, Hämäläinen H, Niemi M, Klaukka T: Use of
secondary preventive medications after the first attack of acute
coronary syndrome. Eur J Cardiovasc Prev Rehabil 2007, , 14: 386-391.
5. Manderbacka K, Keskimäki I, Reunanen A, Klaukka T: Equity in the use of
antithrombotic drugs, beta-blockers and statins among Finnish coronary
patients. Int J Equity Health 2008, 30(7):16.
6. Vehko T, Manderbacka K, Arffman M, Sund R, Reunanen A, Keskimäki I:
Changing patterns of secondary preventive medication among newly
diagnosed coronary heart disease patients with diabetes in Finland: a
register-based study. Scand J Public Health 2010, 38(3):317-324.
7. Hetemaa T, Keskimäki I, Salomaa V, Mähönen M, Manderbacka K,
Koskinen S: Socioeconomic inequities in invasive cardiac procedures
after first myocardial infarction in Finland in 1995. J Clin Epidemiol 2004,
57(3):301-8.
8. Saaristo T, Peltonen M, Keinänen-Kiukaanniemi S, Vanhala M, Saltevo J,
Niskanen L, Oksa H, Korpi-Hyövälti E, Tuomilehto J, for the FIN-D2D Study
Group: National Type 2 Diabetes Prevention Programe in Finland: FIN-
D2D. Int J Circumpolar Health 2007, 66(2):101-112.
9. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ,
Cosentino F, Jonsson B, Laakso M, Malmberg K, Priori S, Ostergren J,
Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P,
Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K,
Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J,
Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E,
Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF,
Parhofer K, Pyörälä K, Raz I, Schernthaner G, Volpe M, Wood D, Task Force
on Diabetes and Cardiovascular Diseases of the European Society of
Cardiology (ESC), European Association for the Study of Diabetes (EASD):
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases:
executive summary. The Task Force on Diabetes and Cardiovascular
Diseases of the European Society of Cardiology (ESC) and of the
European Association for the Study of Diabetes (EASD). Eur Heart J 2007,
28(1):88-136.
10. Seppälä T, Hartikainen J, Häkkinen U, Juntunen M, Linna M, Nikus K,
Pelanteri S, Peltola M, Rauhala A, Vento A: PERFECT - Pallolaajennus ja
ohitusleikkaus: Toimenpiteiden kustannukset ja vaikuttavuus
tuottajatasolla [In Finnish: PERFECT (Performance, Effectiveness and Cost
of Treatment episodes -project) - Coronary revascularizations, cost and
effectiveness]. Helsinki: National Research and Development Centre for
Welfare and Health; 2008.
11. Juntunen M, Sund R, Peltola M, Häkkinen U: Potilasrakenteiden erojen
huomioon ottaminen erikoissairaanhoidon vaikuttavuuden
rekisteritutkimuksessa (In Finnish with an English abstract: Risk-
adjustment in register -based evaluation of hospital care).
Sosiaalilääketieteellinen Aikakauslehti [Journal of Social Medicine in Finland]
2008, 4:258-272.
12. Sund R, Kajantie M, Manderbacka K, Keskimäki I: Socioeconomic inequities
in treatment pathways leading to coronary revascularization in Finland
in 1995-1998. EJPH 2007, 17(Supplement 2):128.
13. Berlin JA, Kimmel SE, Ten Have TR, Sammel MD: An empirical comparison
of several clustered data approaches under confounding due to cluster
effects in the analysis of complications of coronary angioplasty.
Biometrics 1999, 55(2):470-476.
14. Salomaa V, Koukkunen H, Ketonen M, Immonen-Räiha P, Karja-Koskenkari P,
Mustonen J, Lehto S, Torppa J, Lehtonen A, Tuomilehto J, Kesäniemi YA,
Pyörälä K: A new definition for myocardial infarction: what difference
does it make? Eur Heart J 2005, 26(17):1719-1725.
15. Reunanen A: Diabetes. In Health in Finland. Edited by: Koskinen S, Aromaa
A, Huttunen J, Teperi J. National Public Health Institute, Stakes, Ministry of
Social Affairs and Health; 2006:176.
16. Gissler M, Haukka J: Finnish health and social welfare registers in
epidemiological research. Norsk Epidemiologi 2004, 14(1):113-120.
17. Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, Immonen-Räihä P, Karja-
Koskenkari P, Mähönen M, Niemelä M, Kuulasmaa K, Palomäki P,
Mustonen J, Lehtonen A, Arstila M, Vuorenmaa T, Lehto S, Miettinen H,
Torppa J, Tuomilehto J, Kesäniemi YA, Pyörälä K, Salomaa V: The validity of
the Finnish Hospital Discharge Register and Causes of Death Register
data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005,
12(2):132-7.
Vehko et al. BMC Health Services Research 2011, 11:180
http://www.biomedcentral.com/1472-6963/11/180
Page 7 of 818. Hetemaa T, Manderbacka K, Reunanen A, Koskinen S, Keskimäki I:
Socioeconomic inequities in invasive cardiac procedures among patients
with incident angina pectoris or myocardial infarction. Scand J Public
Health 2006, 34(2):116-23.
19. Forssas E, Reunanen A, Keskimäki I, Koskinen S: Coronary heart disease
among diabetic and nondiabetic people – socioeconomic differences in
incidence, prognosis and mortality. J Diabetes Complications 2008,
22(1):10-17.
20. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from
coronary heart disease in subjects with type 2 diabetes and nondiabetic
subjects with and without prior myocardial infarction. N Engl J Med 1998,
339(4):229-234.
21. Soares PR, Hueb WA, Lemos PA, Lopes N, Martinez EE, Cesar LA, Oliveira SA,
Ramires JA: Coronary revascularization (surgical or percutaneous)
decreases mortality after the first year in diabetic subjects but not in
nondiabetic subjects with multivessel disease: an analysis from the
Medicine, Angioplasty, or Surgery Study (MASS II). Circulation 2006, 114(1
Suppl):I420-4.
22. Blustein J, Arons RR, Shea S: Sequential events contributing to variations
in cardiac revascularization rates. Med Care 1995, 33(8):864-880.
23. Bowling A, Bond M, McKee D, McClay M, Banning AP, Dudley N, Elder A,
Martin A, Blackman I: Equity in access to exercise tolerance testing,
coronary angiography, and coronary artery bypass grafting by age, sex
and clinical indications. Heart 2001, 85(6):680-686.
24. Williams JAS, Byles JE, Inder KJ: Equity of access to cardiac rehabilitation:
the role of system factors. Int J Equity Health 2010, 9(2).
25. Alter DA, Iron K, Austin P, Naylor CD, for the SESAMI Study Group:
Socioeconomic status, service patterns, and perceptions of care among
survivors of acute myocardial infarction in Canada. JAMA 2004,
291(9):1100-1107.
26. Hetemaa T, Keskimäki I, Manderbacka K, Leyland A, Koskinen S: How did
the recent increase in the supply of coronary operations in Finland
affect socioeconomic and gender equity in their use? J Epidemiol
Community Health 2003, 57(3):178-85.
27. Vehko T, Manderbacka K, Arffman M, Reunanen A, Keskimäki I: Increasing
resources effected equity in access to revascularizations for patients
with diabetes. Scand Cardiovasc J 2010, 44(4):237-244.
28. Forssas E, Sund R, Manderbacka K, Arffman M, Ilanne-Parikka P, Keskimäki I:
Diabeetikoilla yhä suuri ylikuolleisuus muuhun väestöön verrattuna (In
Finnish with an English abstract: Excess mortality has remained high
among people with diabetes). Suom Laakaril 2010, 26(31):2359-2367.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6963/11/180/prepub
doi:10.1186/1472-6963-11-180
Cite this article as: Vehko et al.: Pathways leading to coronary
revascularisation among patients with diabetes in Finland: a
longitudinal register-based study. BMC Health Services Research 2011
11:180.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Vehko et al. BMC Health Services Research 2011, 11:180
http://www.biomedcentral.com/1472-6963/11/180
Page 8 of 8